Table 2 Targeted drugs had been developed of overlapped genes
From: Transcriptome-wide association studies associated with Crohn’s disease: challenges and perspectives
Genes | Target | Regulatory factor/drug | Disease | Developed process | Clinical trials. gov identifier |
|---|---|---|---|---|---|
GSDMB | GSDMB | Methotrexate | CD | A Phase III randomized, placebo-controlled, double-blind | NCT00132899 |
IL23R | IL23 p19 | Brazikumab | CD | The Phase 3 trial was terminated | NCT03961815 |
Risankizumab | CD | In phase 3, randomized, placebo-controlled, double-blind trial | NCT06063967 | ||
Mirikizumab | CD | In Phase 3 open-label trial | NCT04232553 | ||
Guselkumab | CD | In Phase 3 randomized, placebo-controlled trial | NCT05347095 | ||
IL23R | JNJ-67864238 | CD | Study terminated early as futility criteria met | NCT04102111 | |
TNFSF15 | TNFSF15 | PF-06480605 | UC | Phase 2a single-arm trial | NCT02840721 |